NCT06097260

Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

Name: Clinical Trial NCT06097260
Creator: Pliant Therapeutics, Inc.
Keywords: Idiopathic Pulmonary Fibrosis, PLN-74809, Phase 2, drug, clinical trial, Australia,United States of America

A Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy and Safety of Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF)

Pliant Therapeutics, Inc.·Phase 2·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Idiopathic Pulmonary Fibrosis
Drug/Device/Intervention: PLN-74809
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Pliant Therapeutics, Inc.
Location: Redding,Leesburg,Indianapolis,Omaha,Greensboro,Winston-Salem,Bend,DuBois,Pittsburgh,North Charleston,Franklin,El Paso,McKinney,McKinney,Salt Lake City,Midland, Australia,United States of America

Timeline & enrollment

Phase: Phase 2
Start date: Oct 15, 2023
End date: Sep 30, 2025
Enrollment: 267 participants

Primary outcome

Change from baseline in absolute FVC (mL)

Summary

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).

ICD-10 classifications

Other interstitial pulmonary diseases with fibrosisCystic fibrosis with pulmonary manifestationsCystic fibrosisGraphite fibrosis (of lung)Pulmonary heart disease, unspecified

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06097260
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06097260 through Pure Global AI's free database. This Phase 2 trial is sponsored by Pliant Therapeutics, Inc. and is currently Recruiting. The study focuses on Idiopathic Pulmonary Fibrosis. Target enrollment is 267 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.